

Original Article

Open Access



Predictive value of m6A regulators in prognosis and immunotherapy response of clear cell renal cell carcinoma: a bioinformatics and radiomics analysis

Wanqi Chen^{1,#}, Tuanyu Lin^{2,#}, Zhenshan Wang¹, Liting Zeng¹, Haitao Lin¹, Guisheng Yang¹, Weipeng Huang^{1,2}

¹Department of Medical Imaging Center, Jieyang People's Hospital, Jieyang 522000, Guangdong, China.

²Guangdong Medical University, Zhanjiang 524000, Guangdong, China.

[#]Authors contributed equally.

Correspondence to: Dr. Weipeng Huang, Department of Medical Imaging Center, Jieyang People's Hospital, 107 Tianfu Road, Jieyang 522000, Guangdong, China. E-mail: jyhwp1973@sina.com; Dr. Guisheng Yang, Department of Medical Imaging Center, Jieyang People's Hospital 107 Tianfu Road, Jieyang 522000, Guangdong, China. E-mail: graysonyang0216@foxmail.com

How to cite this article: Chen W, Lin T, Wang Z, Zeng L, Lin H, Yang G, Huang W. Predictive value of m6A regulators in prognosis and immunotherapy response of clear cell renal cell carcinoma: a bioinformatics and radiomics analysis. *J Cancer Metastasis Treat* 2024;10:21. <https://dx.doi.org/10.20517/2394-4722.2024.43>

Received: 24 Apr 2024 **First Decision:** 3 Jun 2024 **Revised:** 13 Jun 2024 **Accepted:** 21 Jun 2024 **Published:** 28 Jun 2024

Academic Editors: Shaoquan Zheng, Ciro Isidoro **Copy Editor:** Fangyuan Liu **Production Editor:** Fangyuan Liu

Abstract

Aim: This study aimed to develop an m6A-related gene signature for predicting the prognosis of clear cell renal cell carcinoma (ccRCC) patients and explore its value in predicting the immunotherapy response.

Methods: In total, 530 ccRCC patients with gene expression data in the TCGA cohort were included and classified into the training ($n = 371$) and validation ($n = 159$) sets. Differential expression analyses of 23 m6A regulators between survivors and non-survivors were performed. Subsequently, an m6A-related gene signature was developed via LASSO Cox regression. All patients were categorized into two groups of m6A subtypes, i.e., low or high m6A score group. The Kaplan-Meier survival curves and Tumor Immune Dysfunction and Exclusion (TIDE) scores of the two m6A subtype groups were compared to measure the gene signature's predictive value in prognosis and potential immunotherapy response, respectively.

Results: Eighteen m6A regulators were significantly differentially expressed between the survivors and non-survivors, and were also related to overall survival (OS). A gene signature containing five selected m6A methylation regulators (*KIAA1429*, *METTL14*, *IGF2BP2*, *IGF2BP3*, and *SRSF2*) was developed and showed favorable



© The Author(s) 2024. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License (<https://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.



discrimination in the training (C-index 0.708) and validation (C-index 0.689) sets. Patients with low m6A scores had significantly better OS and lower TIDE scores than those with high m6A scores. Moreover, a robust MRI-based radiomic signature was developed to noninvasively predict the m6A subtype for each patient.

Conclusion: We demonstrated the prognostic value of five m6A regulators and constructed a gene signature for prognosis and immunotherapy response prediction among ccRCC patients. In addition, a radiomic signature was developed for noninvasive prediction of the m6A subtype. These findings may promote precision medicine and provide novel insights into the regulation of tumor immune microenvironment.

Keywords: Clear cell renal cell carcinoma, m6A, prognosis, immunotherapy response, tumor immune microenvironment, prediction model, radiomics

INTRODUCTION

Renal cell carcinoma (RCC) is among the most common types of cancer globally, holding a position within the top 10. RCC encompasses a group of highly heterogeneous cancers, of which clear cell RCC (ccRCC) is the most common subtype^[1]. Although localized RCC can be managed through ablation, partial or radical nephrectomy or active surveillance^[2], more than 30% of individuals eventually present with or develop metastases, which are refractory to conventional chemotherapy and are associated with high mortality^[3]. Targeted agents against vascular endothelial growth factor (VEGF) and mammalian target of rapamycin (mTOR) pathways have been created for treating metastatic RCC, but the treatment response is varied, and most cases eventually progress^[4]. Downregulation of lactotransferrin promotes metastasis in ccRCC and also renders the ccRCC tumor cells more responsive to mTOR inhibitors, suggesting its potential as a predictor for therapeutic effectiveness^[5]. Over the past decade, marked advances in the treatment of cancers have been made, with immunotherapies being the fourth therapeutic technique for cancer therapy after surgery, chemotherapy, and radiotherapy^[6]. To date, immune checkpoint inhibitors have been demonstrated to bring survival benefits for metastatic RCC^[7]. Nevertheless, most treated patients do not experience effective clinical relief after immunotherapy. For example, the response rate of advanced RCC to nivolumab is only 25%^[8]. For a substantial proportion of patients who are not suitable for immunotherapy, tyrosine kinase inhibitors (TKI) monotherapy remains an appropriate first-line therapy, and may bring lifestyle benefits with treatment breaks^[9]. Therefore, it is urgently needed to predict the prognosis and response to immunotherapy of ccRCC patients and provide individual therapy.

N6-methyladenosine (m6A) modification is a common modification in mRNA of most eukaryotes. The modification is a reversible process regulated by the balanced activities of “writers” (methyltransferases including WTAP, METTL3, and METTL14), “readers” (binding proteins including YTHDF1, YTHDF2, YTHDF3, YTHDC1, and YTHDC2), and “erasers” (demethylases including ALKBH5 and FTO)^[10]. Research has demonstrated that m6A modification plays a pivotal role in the regulation of mRNA metabolism, encompassing various stages such as gene expression, nuclear pre-mRNA processing, cytoplasmic translation, and mRNA decay^[11-13]. In addition, previous studies have indicated that aberrant m6A modification is related to various pathophysiological processes, including developmental defects, dysregulation of cell proliferation, differentiation, and death, as well as tumor progression^[14-16]. Additionally, m6A methylation plays important roles in the innate and adaptive immune response as well as the tumor immune microenvironment^[17]. Moreover, besides exosomes, circulating tumor DNA, and other novel noninvasive tumor biomarkers, substantial evidence has revealed that m6A methylation regulators could be reliable biomarkers for the prediction of the prognosis and/or treatment response of many types of tumors^[18-20]. However, whether m6A methylation regulators could be utilized to predict prognosis and immunotherapy response among patients with ccRCC has not been systematically and rigorously

investigated.

In the presented study, we developed and validated an m6A-related gene signature based on the pretreatment expression of m6A regulators for predicting the prognosis in ccRCC patients and explored the value of the gene signature in predicting immunotherapy response.

METHODS

Data acquisition

The clinical data and gene expression profiles of ccRCC patients were downloaded from The Cancer Genome Atlas (TCGA), and the biological data were normalized. In total, 530 ccRCC cases from the TCGA-KIRC project were involved in the analysis. A total of 23 m6A regulators were extracted, including nine writers (*METTL3*, *RBM15*, *WTAP*, *ZC3H13*, *METTL14*, *METTL16*, *RBM15*, *RBM15B*, and *KIAA1429*), five readers (*YTHDF1*, *YTHDF2*, *YTHDF3*, *IGF2BP1*, *IGF2BP3*, *YTHDC1*, *YTHDC2*, *HNRNPC*, *HNRNPA2B1*, *SRSF2*, *FMR1*, and *ELF3*), and two erasers (*FTO* and *ALKBH5*).

Association between prognosis and m6A regulators

To explore the prognosis value of m6A regulators in ccRCC patients, differentially expressed gene (DEG) analyses were performed to assess their differential expression between survivors and non-survivors among patients with ccRCC. Additionally, we used Wilcoxon's tests to compare the expression levels of m6A regulators between the survivors and non-survivors.

Construction of the gene signature

The gene signature construction flowchart is shown in Figure 1. All cases were randomly split into a training set ($n = 371$) and a validation set ($n = 159$) at a ratio of 7:3. The potential associations between the m6A regulators and overall survival (OS) were estimated with univariable Cox regression analyses in the training set. Among 23 m6A regulators, prognosis-related genes with nonzero coefficients were identified via the least absolute shrinkage and selection operator (LASSO) Cox regression algorithm^[21]. The log-rank tests were used to compare the OS of the low or high expression of the selected prognosis-related m6A regulators, whose thresholds were selected by the "Survminer" package in the R language.

According to the results of the LASSO Cox regression, we developed an m6A-related gene signature for OS prediction among patients with ccRCC, and for individual patients, a risk score (m6A score) was calculated using the subsequent regression equation:

$$\text{m6A score} = b_1G_1 + b_2G_2 + \dots + b_iG_i,$$

where G_i is the selected prognosis-related m6A regulator and b_i is the regression coefficient of G_i .

Performance evaluation of the m6A-related gene signature

We evaluated the discrimination of the m6A-related gene signature by using Harrell's C-index in the training and the validation sets. We also performed time-dependent receiver operating characteristic (ROC) analyses to estimate the predictive accuracy of gene signature. All patients were classified into two m6A subtypes, i.e., low or high m6A score groups, according to their m6A scores, whose threshold was determined using X-tile software in the training set^[22]. The Kaplan-Meier OS curves of the two m6A subtypes were compared by the log-rank tests. Subsequently, a series of stratified analyses were conducted to evaluate the potential modification effects according to age, sex, T stage, N stage, M stage, and tumor grade. To determine whether the m6A subtype is an independent predictor of prognosis in ccRCC, the




Figure 1. The study flowchart. TCGA: The Cancer Genome Atlas; TCIA: the Cancer Imaging Archive; MRI: magnetic resonance imaging; LASSO: least absolute shrinkage and selection operator.

candidate variables were subjected to multivariable analysis based on backward stepwise selection. The discrimination of the significant predictors, as well as their combination, were measured by Harrell's C-indexes.

The predictive value of the m6A subtype in clinical benefit of immunotherapy

The underlying clinical benefit of immunotherapy for ccRCC patients in each m6A subtype was assessed according to the Tumor Immune Dysfunction and Exclusion (TIDE) score. The TIDE score was calculated through the online website (<http://tide.dfci.harvard.edu/>)^[23].

Furthermore, we also investigated the role of prognosis-related m6A regulators in immunity. The CIBERSORT algorithm was used to evaluate the infiltration of 22 types of immunocytes^[24]. Subsequently, the relationship between the identified prognosis-related m6A genes and different types of immunocytes was investigated.

MR images acquisition, images segmentation, and radiomic features extraction

To predict the m6A subtypes individually and noninvasively, we developed an MRI-based radiomic signature. Radiomics is an emerging field of research aiming to extract high-dimensional image-based features from medical images, and to estimate the correlations between the features and potential pathophysiology^[25,26]. Radiomics has recently drawn widespread interest in many cancer studies due to its potential to predict prognosis and treatment outcomes and aid in diagnosis^[25,27,28]. Figure 1 depicts the radiomics workflow of this study. In total, 47 ccRCC patients from the TCIA-KIRC project were enrolled for radiomics analysis. We downloaded the preoperative MRI images from the TCIA (<http://www.cancerimagingarchive.net/>). Tumor image segmentation was performed by using 3D Slicer software (v 4.9.0). Then, extraction of radiomic features was conducted through the *PyRadiomics* platform implanted

in Python software (v 3.9.19)^[29]. A total of 1,316 radiomic features were extracted from each tumor lesion. Subsequently, these feature values were normalized in a linear manner in the range of 0 to 1. The detailed procedure of the radiomics pipeline is described in [Supplementary Method 1](#) and [Supplementary Table 1](#) lists all extracted radiomic features.

Radiomics signature development and performance evaluation

The m6A subtype-related radiomic features were identified by using the LASSO logistic regression algorithm [[Supplementary Method 2](#)]. According to the LASSO logistic regression results, we constructed a radiomics signature to measure the probability of the m6A subtype for individual patients. Based on the LASSO regression formula, a radiomics score for each patient could be calculated. The radiomics signature performance was evaluated according to the area under the ROC curve (AUC). The prognostic value of the radiomic signature in ccRCC patients was estimated by performing univariable Cox regression analysis.

Statistical analysis

R statistical software (v 4.0.4) was used to perform statistical tests. [Supplementary Method 3](#) listed the R packages used in our study. *P* values < 0.05 indicated significant differences.

RESULTS

Association between prognosis and m6A regulators

Baseline characteristics of the enrolled ccRCC patients in the training and validation sets were provided in [Supplementary Table 2](#). Eighteen m6A methylation regulatory genes (*YTHDF1*, *YTHDF2*, *YTHDF3*, *YTHDC1*, *YTHDC2*, *RBM15*, *RBM15B*, *ALKBH5*, *WTAP*, *KIAA1429*, *METTL14*, *METTL16*, *ZC3H13*, *FMR1*, *FTO*, *IGF2BP1*, *IGF2BP2*, and *IGF2BP3*) were differentially expressed between the survivors and non-survivors [[Figure 2A](#)]. Among the survivors, the expression levels of *YTHDF1*, *YTHDF2*, *YTHDF3*, *YTHDC1*, *YTHDC2*, *RBM15*, *RBM15B*, *ALKBH5*, *WTAP*, *KIAA1429*, *METTL14*, *METTL16*, *ZC3H13*, *FTO*, and *FMR1* were significantly decreased compared to the non-survivors, while expression levels of *IGF2BP1*, *IGF2BP2*, and *IGF2BP3* were significantly increased [[Figure 2B](#)].

Construction of the gene signature

As shown in [Figure 3A](#), *YTHDF2*, *YTHDF3*, *YTHDC1*, *YTHDC2*, *RBM15*, *RBM15B*, *KIAA1429*, *METTL14*, *METTL16*, *ZC3H13*, *IGF2BP1*, *IGF2BP2*, *IGF2BP3*, *FMR1*, *FTO*, *SRSF2*, and *HNRNPC* were related to the OS in the univariable Cox regression analysis. In addition, five prognosis-related genes (*KIAA1429*, *METTL14*, *IGF2BP2*, *IGF2BP3*, and *SRSF2*) were selected by the LASSO Cox regression analysis [[Figure 3B-D](#)]. Overall, patients with the low expression of *SRSF2*, *IGF2BP2*, or *IGF2BP3* had better OS compared to those with the high expression, while patients with the high expression of *METTL14* or *KIAA1429* had better OS compared to those with the low expression [[Supplementary Figure 1](#)]. According to the regression results, a gene signature was developed, which can be calculated as an m6A score:

$$\text{m6A score} = 0.0396 \times \text{IGF2BP2} + 0.2196 \times \text{IGF2BP3} + 0.4638 \times \text{SRSF2} - 0.5850 \times \text{KIAA1429} - 0.0615 \times \text{METTL14}.$$

Performance evaluation of the m6A-related gene signature

C-index for the gene signature was 0.708 in the training set (95% confidence interval [CI]: 0.660-0.756) and 0.689 in the validation set (95%CI: 0.611-0.767). The time-ROC curve analysis also demonstrated satisfactory predictive accuracy for the gene signature. In the 3-year and 5-year ROC curves, the AUCs were 0.715 (95%CI: 0.657-0.772) and 0.746 (95%CI: 0.689-0.803) in all patients, 0.724 (95%CI: 0.656-0.792) and 0.744 (95%CI: 0.677-0.812) in the training set, and 0.698 (95%CI: 0.590-0.806) and 0.766 (95%CI: 0.662-0.870) in the validation set, respectively [[Figures 4A-C](#)]. After calculating the m6A scores




Figure 2. Association between the expression of m6A methylation regulators and prognosis in ccRCC patients. (A) The heatmap exhibits the expression patterns of the 23 m6A methylation regulators between the survivors and non-survivors. (B) The violin plots show the differential expression of the 23 m6A methylation regulators in the survivors (blue) and the non-survivors (red). ccRCC: Clear cell renal cell carcinoma. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$.

from the gene signature, the patients were categorized into two groups of m6A subtypes, i.e., the low and high m6A score groups, on account of the threshold of 1.10 [Supplementary Figure 2]. Overall, compared with patients with high m6A scores, those with low m6A scores had better OS [Figure 4D]; the same results were also found in the training or validation set [Figure 4E and F], as well as in different subgroups regarding age, sex, T, N, M stage, and tumor grade [Figure 5].

Based on the multivariable Cox regression analyses, five variables were determined as the independent predictors of OS, including age, tumor grade, N stage, M stage, and m6A subtype [Supplementary Table 3]. Moreover, the m6A score achieved better discrimination than other clinical predictors [Supplementary Table 4].

Genetic mutation landscape analysis

A total of 391 ccRCC patients with genetic mutation data were enrolled to analyze the genetic mutation landscape for ccRCC lesions, including 105 patients with high m6A scores and 286 patients with low m6A scores. The identified somatic mutations were compared between the two different m6A subtypes [Supplementary Figure 3A]. Among patients with high m6A scores, *VHL*, *PBRM1*, *SETD2*, *BAP1*, and *TTN*




Figure 3. Development of the m6A-based gene signature. (A) Univariable Cox regression analyses measuring the predictive value of m6A methylation regulators for overall survival of ccRCC patients. (B) Tuning parameter (λ) selection in the LASSO model used 10-fold cross-validation via minimum criteria. Partial likelihood deviances from the LASSO regression cross-validation procedure were drawn as a function of $\log(\lambda)$. The numbers along the upper x-axis represent the average number of predictors. The red dots show the average deviance values for each model with a given λ , and the vertical bars through the red dots indicate the upper and lower values of the deviance. The dotted vertical lines are plotted at the optimal values where the model provides its best fit to the data. The optimal λ value of 0.038 with $\log(\lambda) = -3.279$ was identified. (C) LASSO coefficient profiles of the 23 m6A methylation regulators. The dotted vertical line is plotted at the value determined by using 10-fold cross-validation in (B), where optimal λ resulted in 5 nonzero coefficients. (D) Histogram showing the coefficients of the selected m6A regulators in the gene signature. ccRCC: Clear cell renal cell carcinoma; LASSO: least absolute shrinkage and selection operator.

were the five genes with the highest mutation frequency [Supplementary Figure 3B], while *VHL*, *PBRM1*, *TTN*, *MUC16*, and *SETD2* were the genes with top five mutation frequencies in patients with low m6A scores [Supplementary Figure 3C].

The predictive value of the m6A subtype in clinical benefit of immunotherapy

To further assess the predictive value of the m6A subtype in immunotherapy efficacy, the TIDE score, T cell dysfunction score, microsatellite instability (MSI) score, and T cell exclusion score were calculated for each patient. As shown in Figures 6A and B, the TIDE score and T cell dysfunction score were significantly lower in patients with low m6A scores than those with high m6A scores. Meanwhile, a lower m6A score was associated with a higher MSI score [Figure 6C]. According to these findings, patients in the low m6A score group were more likely to achieve a positive immunotherapy response. However, the T cell exclusion score did not differ significantly between the two groups [Figure 6D].

Moreover, as shown in Figure 7, among those selected prognosis-related m6A regulators, *IGF2BP3* was positively correlated with activated CD4⁺ memory T cells. *METTL14* was negatively correlated with follicular helper T cells and regulatory T cells. *KIAA1429* was negatively correlated with follicular helper T




Figure 4. Correlation between the gene signature and prognosis in ccRCC patients. (A-C) Time-ROC curve analyses of the m6A score in all patients (A), the training set (B), and the validation set (C), respectively. (D-F) Kaplan-Meier survival curves of patients divided into low and high m6A score groups in all patients (D), the training set (E), and the validation set (F), respectively. ccRCC: Clear cell renal cell carcinoma; ROC: receiver operator characteristic curve.

cells, regulatory T cells, and activated NK cells.

Radiomics signature development and performance evaluation

In total, 7 prognosis-related features were determined by the LASSO logistic regression [Figures 8A and B]. The selected prognosis-related features' coefficients are provided in Figure 8C. An AUC of 0.915 (95%CI: 0.835-0.996; Figure 8D) suggested that the radiomics signature had satisfactory discrimination for m6A subtypes prediction. Based on the maximum Youden index, an optimal radiomics score cutoff was chosen as -0.537. The waterfall plot illustrates the distribution of radiomics scores and m6A subtypes for all patients, with the dividing line delineated at the threshold value [Figure 8E]. Moreover, based on the univariable Cox regression, the radiomic signature was determined to be a significant predictor of the OS among patients with ccRCC (hazard ratio: 1.717, 95%CI: 1.080-2.730; $P = 0.022$).

DISCUSSION

According to the pretreatment expression of 5 prognosis-related m6A methylation regulators, we developed and validated a gene signature to predict the ccRCC patient prognosis, and assessed the predictive value of the gene signature for immunotherapy response. According to the gene signature, patients could be categorized into two m6A subtypes, indicating different prognoses. Moreover, we developed an MRI-based radiomic signature, which can serve as a noninvasive tool for individualized prediction of the m6A subtypes. It would help develop therapeutic schemes and promote precision medicine.




Figure 5. Stratified analyses of the m6A subtype. Stratified analyses were applied to determine the performance of the m6A subtype in various subgroups according to age (A and B), sex (C and D), T stage (E and F), N stage (G and H), M stage (I and J), and tumor grade (K and L).

Our study revealed that eighteen m6A regulators (*YTHDF1*, *YTHDF2*, *YTHDF3*, *YTHDC1*, *YTHDC2*, *RBM15*, *RBM15B*, *ALKBH5*, *WTAP*, *KIAA1429*, *METTL14*, *METTL16*, *ZC3H13*, *FMR1*, *FTO*, *IGF2BP1*, *IGF2BP2*, and *IGF2BP3*) were differentially expressed between survivors and non-survivors, whose expression was related to OS as well. Our findings preliminarily suggest that these eighteen m6A regulators may affect the malignant behavior of renal carcinoma cells.

Subsequently, by incorporating five selected m6A regulators (*KIAA1429*, *METTL14*, *IGF2BP2*, *IGF2BP3*, and *SRSF2*), we developed a gene signature to predict OS among ccRCC patients. The gene signature can accurately predict the prognosis of ccRCC patients. Moreover, both the TIDE score and T-cell dysfunction score were lower in the low m6A score group, while the MSI score was higher. These scores can indicate the potential ability of immune evasion of cancer and could be used to predict immunotherapy response^[23]. In addition, three prognosis-related m6A regulators (*IGF2BP3*, *METTL14*, and *KIAA1429*) were found to be correlated with specific immune cell types. These results indicate that the m6A modification plays a vital role in the tumor immune microenvironment. In light of this, our results demonstrated that patients with low m6A scores may have a lower probability of tumor cells escaping from the surveillance of the immune system and, thus, would be more likely to achieve a positive immunotherapy response. This also indicates the favorable value of the m6A subtype in predicting immunotherapy benefits. Our study will provide novel insights into the regulation of tumor immune microenvironment. Additionally, the presented gene signature will aid clinicians in determining whether the prognosis or immunotherapy response of a patient




Figure 6. The probable benefit of patients for immunotherapy in different m6A subtypes. (A) TIDE score, (B) T cell dysfunction score, (C) MSI, and (D) T cell exclusion score in different groups of m6A subtypes. The scores between the two groups were compared through the Wilcoxon tests. TIDE: Tumor Immune Dysfunction and Exclusion; MSI: microsatellite instability.

is good or bad, thus facilitating the development of more appropriate treatment plans that are more conducive to the allocation of medical and health resources.

In the present study, based on LASSO Cox regression analysis, five m6A regulators, including *METTL14*, *KIAA1429*, *IGF2BP2*, *IGF2BP3*, and *SRSF2*, were identified as critical predictors of OS in ccRCC patients. Among them, *METTL14* is a close counterpart of *METTL3* and an integral part of the multiprotein methyltransferase complex^[30], which can stabilize *METTL3*, maintain complex integrity, and facilitate RNA binding^[31]. Compared to each protein alone, the stabilized complex formed by the *METTL3*-*METTL14* heterodimer exhibits enhanced methyltransferase activity^[30,32]. Previous studies revealed the low expression of *METTL14* in ccRCC, and the downregulation of *METTL14* is related to poor OS^[33,34], which was also found in our study. In addition to ccRCC, decreased expression of *METTL14* was demonstrated in glioblastoma stem cells^[35], whereas upregulation of *METTL14* in acute myeloid leukemia promoted leukemogenesis^[36].

The RNA-binding protein *KIAA1429* is localized in nuclear speckles^[37]. Knockdown of *KIAA1429* leads to a diminished expression of m6A, with a decrease that is more pronounced compared to depletion observed by the knockdown of *METTL3* or *METTL4* alone, indicating the important role of *KIAA1429* in the




Figure 7. The relationship of the selected m6A regulators with different types of immune cells. (A) The heatmap shows the relationship between the expression levels of the selected m6A regulators and different types of immunocytes. (B-G) Correlation plots exhibit the relationship between the selected m6A regulators and different types of immunocytes. Only the relationship with the absolute value of correlation coefficients no less than 0.3 was displayed.

multiprotein methyltransferase complex^[37]. Consistent with our study, a previous study revealed that the *KIAA1429* expression is decreased in ccRCC patients, and downregulation is associated with shortened survival following nephrectomy^[33]. However, a few studies supposed that *KIAA1429* might enhance the generation and progression of tumors, such as hepatocellular carcinoma and breast cancer^[38,39].

In agreement with our study, several previous studies also demonstrated that elevated expression of *IGF2BP2* and *IGF2BP3* was significantly related to shortened OS of ccRCC patients^[34,40,41]. Moreover, the expression of *IGF2BP2* and *IGF2BP3* was positively related to activated central memory CD8+ T cells and CD4+ T cells^[40]. Therefore, we hypothesized that the dysregulation of *IGF2BP2* and *IGF2BP3* may influence the associated immune cells and thus affect the survival of ccRCC patients. In addition, *IGF2BP2* was reported to be differentially expressed in pancreatic cancer, and its high expression promotes tumor growth by stimulating the PI3K/Akt pathway^[42].




Figure 8. Development and performance evaluation of the MRI-based radiomics signature. (A) Tuning parameter (λ) selection in the LASSO model used 10-fold cross-validation via minimum criteria. The optimal λ value of 0.096 with log(λ) = -2.339 was identified. (B) LASSO coefficient profiles of the 1,316 radiomic features. The dotted vertical line is drawn at the value selected using 10-fold cross-validation in (A), where optimal λ resulted in 7 nonzero coefficients. (C) Histogram showing the coefficients of the selected features in the radiomics signature. The radiomics score was calculated as a linear combination of the 7 selected features weighted by their respective coefficients. (D) ROC curve of the gene signature. (E) Waterfall plot for distribution of radiomics scores and m6A subtypes in all patients. LASSO: Least absolute shrinkage and selection operator; ROC: receiver operator characteristic curve; LoG: laplacian of gaussian; GLSZM: gray level size zone matrix; GLRLM: gray level run length matrix; GLCM: gray level cooccurrence matrix; LRHGLE: long run high gray level emphasis; IDN: inverse difference normalized; LAHGLE: large area high gray level emphasis; IMC2: informal measure of correlation 2.

The SRSF2 protein belongs to the SR family of proteins that regulate constitutive and alternative splicing^[43]. SRSF2 is a key predictor of OS in ccRCC patients in this study. SRSF2 causes apoptosis by regulating the alternative splicing of some apoptosis-associated genes in lung cancer^[44], suggesting that SRSF2 can lead to tumorigenesis. Several studies also revealed that silencing of SRSF2 resulted in the upregulation of TP53, which generally functions as an apoptotic protein^[45,46]. However, p53 can also be considered an activator of anti-apoptosis in several tumor cells^[47-49]. In renal cancer, upregulation of p53 is related to tumor metastasis

and worse prognosis in patients^[50].

To further elucidate the biological implications of our m6A-related gene signature, it is noteworthy to focus on the behavior of cancer stem cells (CSCs) in ccRCC, given their significant impact on tumor relapse and treatment resistance. A recent study discovered a subset of CD133⁺/CD24⁺ CSCs in ccRCC, which exhibited self-renewal and clonogenic capabilities, leveraging pathways such as Notch, Wnt, and Hedgehog - commonly involved in early embryogenesis and also affected by m6A modifications^[51]. Investigating the intersection of m6A methylation regulators with these CSC pathways could provide novel insights into their roles in sustaining CSC populations and affecting tumor heterogeneity, thereby potentially improving the predictive accuracy of our gene signature for both prognosis and therapeutic responses. Other significant biomarkers such as MUC1, a glycoprotein known for its role in epithelial tumor biology, may also play a vital role in how m6A modifications influence ccRCC pathology. MUC1 is frequently overexpressed in RCC and influences crucial processes including cell proliferation and metabolic reprogramming^[52,53]. The interaction between MUC1 overexpression and m6A methylation patterns could provide deeper insights into the regulatory networks that drive ccRCC progression and resistance to therapy. Exploring these connections might uncover new layers of complexity within the tumor microenvironment and highlight potential synergies between epigenetic modifications and membrane protein dynamics, offering novel avenues for targeted therapeutic interventions^[52].

Notably, the m6A subtypes can only be determined in an invasive way. For patients who are planning to receive neoadjuvant immunotherapy or patients who are unable to undergo surgical treatment in an advanced stage, a tumor biopsy is required to obtain information about m6A subtypes; however, this procedure is prone to some adverse effects such as bleeding and tumor dissemination. Therefore, we developed a reliable radiomic signature to predict the m6A subtypes noninvasively in ccRCC patients. The high-throughput features could provide more comprehensive information about tumors and would be more sensitive to determining the m6A subtype, which will be helpful in estimating the prognosis and immunotherapy response. Additionally, our research design may be applicable to other cancer studies. The study results may also offer new perspectives on cancer diagnosis, treatment, or patient management in other tumor types.

There are several limitations to our study. First, even though substantial evidence has shown that m6A regulatory genes are crucial for predicting the prognosis of ccRCC patients, the underlying mechanisms remain unknown and warrant further exploration by experiments on cell lines and human tissues. Second, due to the retrospective design of the study, potential biases are present, such as selection bias, information bias, and confounding bias. Third, because of the shortcomings inherent in bioinformatics analysis performed in this study, in future clinical applications, data from different sources need to be standardized to ensure effective integration, and medical professionals need to receive appropriate training to understand and apply the analysis results of this study. Moreover, the prediction efficacy of the gene signature and radiomic signature needs to be further externally validated to guarantee the generality and reliability of this study.

CONCLUSIONS

In our study, we identified five critical prognosis-related m6A regulators in ccRCC patients. Additionally, the presented m6A-related gene signature could aid in predicting the OS and immunotherapy response of ccRCC patients. Moreover, the radiomic signature can be used as a noninvasive tool for predicting the m6A subtypes individually. It is necessary to verify the robustness of the two signatures by multicenter validation before they are applied in clinical settings.

DECLARATIONS

Acknowledgments

We thank the Cancer Genome Atlas (TCGA) for the gene and clinical datasets. We also thank the Cancer Imaging Archive (TCIA) for the MRI datasets. We also thank Figdraw for the assistance in drawing graphical abstract (www.figdraw.com).

Authors' contributions

Designed the study: Chen W, Lin T, Yang G, Huang W

Processed the images: Wang Z, Zeng L, Lin H

Supervised the study: Yang G, Huang W

All the authors analyzed and interpreted the data, and wrote, reviewed, and/or revised the manuscript, and approved the submitted version

Availability of data and materials

Publicly available datasets were analyzed in this study. This data can be found here: the Cancer Genome Atlas (TCGA, <https://portal.gdc.cancer.gov/>); the Cancer Imaging Archive (TCIA, <http://www.cancerimagingarchive.net/>).

Financial support and sponsorship

None.

Conflicts of interest

All authors declare that there are no conflicts of interest.

Ethical approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Copyright

© The Author(s) 2024.

REFERENCES

1. Rini BI, Campbell SC, Escudier B. Renal cell carcinoma. *Lancet* 2009;373:1119-32. DOI PubMed
2. Ljungberg B, Bensalah K, Canfield S, et al. EAU guidelines on renal cell carcinoma: 2014 update. *Eur Urol* 2015;67:913-24. DOI
3. Wolff I, May M, Hoschke B, et al. Do we need new high-risk criteria for surgically treated renal cancer patients to improve the outcome of future clinical trials in the adjuvant setting? *Eur J Surg Oncol* 2016;42:744-50. DOI
4. Motzer RJ, Hutson TE, McCann L, Deen K, Choueiri TK. Overall survival in renal-cell carcinoma with pazopanib versus sunitinib. *N Engl J Med* 2014;370:1769-70. DOI PubMed
5. Aweys H, Lewis D, Sheriff M, et al. Renal cell cancer - insights in drug resistance mechanisms. *Anticancer Res* 2023;43:4781-92. DOI
6. Hsieh JJ, Purdue MP, Signoretti S, et al. Renal cell carcinoma. *Nat Rev Dis Primers* 2017;3:17009. DOI PubMed PMC
7. Choueiri TK, Motzer RJ. Systemic therapy for metastatic renal-cell carcinoma. *N Engl J Med* 2017;376:354-66. DOI PubMed
8. Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. *N Engl J Med* 2015;373:1803-13. DOI
9. Brown JE, Royle KL, Gregory W, et al. Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial. *Lancet Oncol* 2023;24:213-27. DOI
10. Yang Y, Hsu PJ, Chen YS, Yang YG. Dynamic transcriptomic m⁶A decoration: writers, erasers, readers and functions in RNA metabolism. *Cell Res* 2018;28:616-24. DOI PubMed PMC

11. Paramasivam A, Priyadharsini JV, Raghunandhakumar S. Implications of m⁶A modification in autoimmune disorders. *Cell Mol Immunol* 2020;17:550-1. DOI PubMed PMC
12. Paramasivam A, Vijayashree Priyadharsini J. Novel insights into m⁶A modification in circular RNA and implications for immunity. *Cell Mol Immunol* 2020;17:668-9. DOI PubMed PMC
13. Paramasivam A, Vijayashree Priyadharsini J, Raghunandhakumar S. N⁶-adenosine methylation (m⁶A): a promising new molecular target in hypertension and cardiovascular diseases. *Hypertens Res* 2020;43:153-4. DOI PubMed
14. Fu Y, Dominissini D, Rechavi G, He C. Gene expression regulation mediated through reversible m⁶A RNA methylation. *Nat Rev Genet* 2014;15:293-306. DOI PubMed
15. Tong J, Cao G, Zhang T, et al. m⁶A mRNA methylation sustains Treg suppressive functions. *Cell Res* 2018;28:253-6. DOI PubMed PMC
16. Pinello N, Sun S, Wong JJ. Aberrant expression of enzymes regulating m⁶A mRNA methylation: implication in cancer. *Cancer Biol Med* 2018;15:323-34. DOI PubMed PMC
17. Guo L, Yang H, Zhou C, Shi Y, Huang L, Zhang J. N⁶-methyladenosine RNA modification in the tumor immune microenvironment: novel implications for immunotherapy. *Front Immunol* 2021;12:773570. DOI PubMed PMC
18. Wang P, Wang X, Zheng L, Zhuang C. Gene signatures and prognostic values of m⁶A regulators in hepatocellular carcinoma. *Front Genet* 2020;11:540186. DOI PubMed PMC
19. Zhao R, Li B, Zhang S, et al. The N⁶-methyladenosine-modified pseudogene HSPA7 correlates with the tumor microenvironment and predicts the response to immune checkpoint therapy in glioblastoma. *Front Immunol* 2021;12:653711. DOI PubMed PMC
20. Xu W, Tian X, Liu W, et al. m⁶A regulator-mediated methylation modification model predicts prognosis, tumor microenvironment characterizations and response to immunotherapies of clear cell renal cell carcinoma. *Front Oncol* 2021;11:709579. DOI PubMed PMC
21. Tibshirani R. Regression shrinkage and selection via the lasso: a retrospective. *J R Stat Soc Series B* 2011;73:273-82. DOI
22. Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. *Clin Cancer Res* 2004;10:7252-9. DOI PubMed
23. Jiang P, Gu S, Pan D, et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. *Nat Med* 2018;24:1550-8. DOI PubMed PMC
24. Chen B, Khodadoust MS, Liu CL, Newman AM, Alizadeh AA. Profiling tumor infiltrating immune cells with CIBERSORT. In: von Stechow L, editor. *Cancer Systems Biology*. New York: Springer; 2018. pp. 243-59. DOI PubMed PMC
25. Lambin P, Leijenaar RTH, Deist TM, et al. Radiomics: the bridge between medical imaging and personalized medicine. *Nat Rev Clin Oncol* 2017;14:749-62. DOI
26. Zheng J, Yu H, Batur J, et al. A multicenter study to develop a non-invasive radiomic model to identify urinary infection stone in vivo using machine-learning. *Kidney Int* 2021;100:870-80. DOI
27. Cai J, Zheng J, Shen J, et al. A radiomics model for predicting the response to bevacizumab in brain necrosis after radiotherapy. *Clin Cancer Res* 2020;26:5438-47. DOI
28. Zheng J, Kong J, Wu S, et al. Development of a noninvasive tool to preoperatively evaluate the muscular invasiveness of bladder cancer using a radiomics approach. *Cancer* 2019;125:4388-98. DOI
29. van Griethuysen JJM, Fedorov A, Parmar C, et al. Computational radiomics system to decode the radiographic phenotype. *Cancer Res* 2017;77:e104-7. DOI PubMed PMC
30. Cao G, Li HB, Yin Z, Flavell RA. Recent advances in dynamic m⁶A RNA modification. *Open Biol* 2016;6:160003. DOI PubMed PMC
31. Wang X, Feng J, Xue Y, et al. Structural basis of N⁶-adenosine methylation by the METTL3-METTL14 complex. *Nature* 2016;534:575-8. DOI
32. Liu J, Yue Y, Han D, et al. A METTL3-METTL14 complex mediates mammalian nuclear RNA N⁶-adenosine methylation. *Nat Chem Biol* 2014;10:93-5. DOI PubMed PMC
33. Gundert L, Strick A, von Hagen F, et al. Systematic expression analysis of m⁶A RNA methyltransferases in clear cell renal cell carcinoma. *BJUI Compass* 2021;2:402-11. DOI PubMed PMC
34. Xu T, Gao S, Ruan H, et al. METTL14 acts as a potential regulator of tumor immune and progression in clear cell renal cell carcinoma. *Front Genet* 2021;12:609174. DOI PubMed PMC
35. Cui Q, Shi H, Ye P, et al. m⁶A RNA methylation regulates the self-renewal and tumorigenesis of glioblastoma stem cells. *Cell Rep* 2017;18:2622-34. DOI PubMed PMC
36. Weng H, Huang H, Wu H, et al. METTL14 inhibits hematopoietic stem/progenitor differentiation and promotes leukemogenesis via mRNA m⁶A modification. *Cell Stem Cell* 2018;22:191-205.e9. DOI PubMed PMC
37. Xie W, Wei L, Guo J, Guo H, Song X, Sheng X. Physiological functions of Wilms' tumor 1-associating protein and its role in tumorigenesis. *J Cell Biochem* 2019;120:10884-92. DOI
38. Qu N, Qin S, Zhang X, et al. Multiple m⁶A RNA methylation modulators promote the malignant progression of hepatocellular carcinoma and affect its clinical prognosis. *BMC Cancer* 2020;20:165. DOI PubMed PMC
39. Qian JY, Gao J, Sun X, et al. KIAA1429 acts as an oncogenic factor in breast cancer by regulating CDK1 in an N⁶-methyladenosine-independent manner. *Oncogene* 2019;38:6123-41. DOI
40. Li J, Cao J, Liang C, Deng R, Li P, Tian J. The analysis of N⁶-methyladenosine regulators impacting the immune infiltration in clear

- cell renal cell carcinoma. *Med Oncol* 2022;39:41. [DOI](#)
41. Xing Q, Luan J, Liu S, Ma L, Wang Y. Six RNA binding proteins (RBPs) related prognostic model predicts overall survival for clear cell renal cell carcinoma and is associated with immune infiltration. *Bosn J Basic Med Sci* 2022;22:435-52. [DOI](#) [PubMed](#) [PMC](#)
 42. Xu X, Yu Y, Zong K, Lv P, Gu Y. Up-regulation of IGF2BP2 by multiple mechanisms in pancreatic cancer promotes cancer proliferation by activating the PI3K/Akt signaling pathway. *J Exp Clin Cancer Res* 2019;38:497. [DOI](#) [PubMed](#) [PMC](#)
 43. Long JC, Caceres JF. The SR protein family of splicing factors: master regulators of gene expression. *Biochem J* 2009;417:15-27. [DOI](#) [PubMed](#)
 44. Merdzhanova G, Edmond V, De Seranno S, et al. E2F1 controls alternative splicing pattern of genes involved in apoptosis through upregulation of the splicing factor SC35. *Cell Death Differ* 2008;15:1815-23. [DOI](#)
 45. Haupt S, Berger M, Goldberg Z, Haupt Y. Apoptosis - the p53 network. *J Cell Sci* 2003;116:4077-85. [DOI](#) [PubMed](#)
 46. Kędzierska H, Popławski P, Hoser G, et al. Decreased expression of SRSF2 splicing factor inhibits apoptotic pathways in renal cancer. *Int J Mol Sci* 2016;17:1598. [DOI](#) [PubMed](#) [PMC](#)
 47. Garner E, Martinon F, Tschopp J, Beard P, Raj K. Cells with defective p53-p21-pRb pathway are susceptible to apoptosis induced by p84N5 via caspase-6. *Cancer Res* 2007;67:7631-7. [DOI](#) [PubMed](#)
 48. Mercer J, Figg N, Stoneman V, Braganza D, Bennett MR. Endogenous p53 protects vascular smooth muscle cells from apoptosis and reduces atherosclerosis in ApoE knockout mice. *Circ Res* 2005;96:667-74. [DOI](#) [PubMed](#)
 49. Amin AR, Thakur VS, Gupta K, et al. Restoration of p53 functions protects cells from concanavalin A-induced apoptosis. *Mol Cancer Ther* 2010;9:471-9. [DOI](#)
 50. Haitel A, Wiener HG, Baethge U, Marberger M, Susani M. mdm2 expression as a prognostic indicator in clear cell renal cell carcinoma: comparison with p53 overexpression and clinicopathological parameters. *Clin Cancer Res* 2000;6:1840-4. [PubMed](#)
 51. Lasorsa F, Rutigliano M, Milella M, et al. Cancer stem cells in renal cell carcinoma: origins and biomarkers. *Int J Mol Sci* 2023;24:13179. [DOI](#) [PubMed](#) [PMC](#)
 52. Lucarelli G, Netti GS, Rutigliano M, et al. MUC1 expression affects the immunoflogosis in renal cell carcinoma microenvironment through complement system activation and immune infiltrate modulation. *Int J Mol Sci* 2023;24:4814. [DOI](#) [PubMed](#) [PMC](#)
 53. Lucarelli G, Rutigliano M, Loizzo D, et al. MUC1 tissue expression and its soluble form CA15-3 identify a clear cell renal cell carcinoma with distinct metabolic profile and poor clinical outcome. *Int J Mol Sci* 2022;23:13968. [DOI](#) [PubMed](#) [PMC](#)